Background/Objectives: Remimazolam, a short-acting benzodiazepine, promotes quick and consistent recovery from anesthesia. However, flumazenil’s rapid antagonistic effects on benzodiazepines during the emergence from anesthesia are thought to increase the risk of postoperative nausea and vomiting (PONV). This study aimed to compare the rate of PONV in monitored anesthesia care (MAC) with remimazolam versus conventional MAC with dexmedetomidine. Methods: This single-center retrospective study included all cases with transcatheter aortic valve replacements (TAVR) performed using MAC at our institution between January 2019 and April 2023. The patients were divided into remimazolam and dexmedetomidine–propofol groups based on the anesthetic method used. We used propensity score matching at a 1:1 ratio to account for the patient backgrounds. The primary outcome measure was the rate of PONV within 48 h. Secondary outcome measures included the severity of PONV and the number of antiemetics administered. Results: This study included 177 subjects. Following propensity score matching, 61 patients were allocated to each group. The incidence of PONV within 48 h after surgery was 4.92% in the remimazolam group and 3.28% in the dexmedetomidine–propofol group, with no significant difference between the two groups (p = 0.817). There was no significant difference between the two groups in terms of the secondary outcomes, including the severity of PONV (p = 0.190) and the use of antiemetics (p = 0.690). Conclusions: In TAVR with MAC and remimazolam, the incidence of PONV within 48 h was comparable to that of dexmedetomidine.
Background/Objectives: Monitored anesthesia care (MAC) is increasingly used for transcatheter aortic valve replacement (TAVR), where rapid recovery of consciousness may facilitate early postoperative neurological assessment. Remimazolam provides sedation that can be pharmacologically reversed with flumazenil. We compared emergence from sedation between a remimazolam–flumazenil-based MAC strategy and a conventional dexmedetomidine-based strategy in patients undergoing transfemoral TAVR. Methods: In this single-center randomized controlled trial, 84 patients undergoing transfemoral TAVR were randomized 1:1 to remimazolam–remifentanil (R group) or dexmedetomidine–propofol–remifentanil (D group) MAC. Flumazenil was administered at the initiation of the postoperative awakening attempt in the R group. The primary outcome was arousal time, assessed using two prespecified measures: time from discontinuation of all anesthetic infusions to arousal and time from initiation of the postoperative awakening attempt to arousal. Arousal was defined as a Modified Observer’s Assessment of Alertness/Sedation score of 5. Results: Eighty-three patients were included in the analysis (R group, n = 42; D group, n = 41). The time from discontinuation of all anesthetic infusions to arousal was shorter in the R group than in the D group (19.05 [15.77–23.59] vs. 24.09 [19.25–34.78] min; p = 0.0045). The time from initiation of the awakening attempt to arousal was also shorter (0.60 [0.33–1.00] vs. 1.00 [0–4.72] min; p = 0.0117). No patient in the R group required rescue propofol. No significant between-group differences were observed in major procedural or postoperative outcomes. Conclusions: A remimazolam-based MAC strategy with flumazenil reversal provided faster and more reliable emergence from sedation than a conventional dexmedetomidine-based strategy during transfemoral TAVR. These findings suggest that a reversible sedation strategy may facilitate rapid recovery of consciousness when early postoperative assessment is desired, although its impact on neurological or other clinical outcomes remains to be established.